An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

These and other GLP1-RA diabetes/weight-loss meds can also boost outcomes for folks battling chronic kidney disease, new ...

Ozempic, the blockbuster GLP-1 drug that was originally approved to treat type 2 diabetes, has now also been approved by the ...

Long-term weight stability is recommended to improve health outcomes in individuals with type 1 diabetes. Chronic kidney disease has been linked to yo-yo dieting (also known as body-weight cycling ...

Body-weight cycling (also known as yo-yo dieting) has been shown to significantly increase the risk of kidney disease in people with type 1 diabetes, regardless of body mass index (BMI) and other ...

These drugs, called GLP1-RAs (short for glucagon-like peptide-1 receptor agonists), have been found to reduce hospital visits ...

Diabetic nephropathy is a progressive kidney disease associated with diabetes mellitus – type 1 and type 2 – affecting kidney glomeruli, arterioles, tubules and the interstitium. Clinical ...

The Food and Drug Administration (FDA) on Tuesday approved Ozempic (semaglutide) to reduce the risk of complications and death in adults with both type 2 diabetes and chronic kidney disease. This ...

Elevated serum fibroblast growth factor 23 levels at baseline are linked to a 29% increased risk for diabetic kidney disease, ...

Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional ... It also ranks No. 1 in New York according to Newsweek ...